Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

 

This appeal hearing will hear appeals against the Final Appraisal Document for the above technology submitted by the following organisations:

  • Fight Bladder Cancer
  • Action Bladder Cancer UK
  • Merck Serono Ltd
  • British Uro-Oncology Group
  • Association of Cancer Physicians

 

The appeal panel will convene on Tuesday 28 September 2021 from 10am on Zoom, to hear oral representation from the appellants.


This page was last updated: